openPR Logo
Press release

Rheumatology Therapeutics Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030

10-28-2023 05:49 PM CET | Health & Medicine

Press release from: Orion Market Research

Rheumatology Therapeutics Market Share, Trends, Future

The global rheumatology therapeutics market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). The growth of the rheumatology therapeutics market is primarily driven by the increased utilization of disease-modifying anti-rheumatic medicines (DMARDs) for targeted disease treatment. Recent steps in rheumatology have led to a diverse range of drug options available to rheumatologists, particularly for managing rheumatic joint disorders. The World Health Organization (WHO) reported that around 18 million individuals were living with rheumatoid arthritis globally in 2019. This condition predominantly affects women (70%) and those aged over 55 (55%).

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/rheumatology-therapeutics-market

One such condition, Polymyalgia rheumatica, can severely impair daily activities due to its flares of painful symptoms across multiple body areas An approval by the FDA for a steroid-free treatment for polymyalgia rheumatica marks a significant step in treatment. For instance, in March 2023, for sarilumab (Kevzara), an interleukin (IL) 6 receptor antagonist, gained FDA approval for individuals with polymyalgia rheumatica who have either failed glucocorticoid treatment or cannot tolerate its tapering.

Often, patients with psoriatic arthritis are not able not suspect a connection between their psoriasis skin symptoms and the joint pain, swelling and stiffness, resulting in delayed diagnosis and treatment. For instance, in January 2022, AbbVie released FDA-approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30% of patients with psoriasis. Ankylosing spondylitis (AS) is a chronic, inflammatory disease of the axial spine. Chronic back pain and progressive spinal stiffness are the most common features of this disease. For instance, in November 2021, Pfizer Inc. announced that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.

Market Coverage

• The market number available for - 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Drug Type
o By Disease Indication
o By Category
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Merck & Co., Inc., Novartis AG, Pfizer Inc. and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Rheumatology Therapeutics Market Report Segment

By Drug Type

• Disease-modifying Anti-rheumatic Drugs
• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Uric Acid Drugs
• Others

By Disease Indication

• Rheumatoid Arthritis
• Osteoarthritis
• Gout
• Psoriatic Arthritis
• Ankylosing Spondylitis

By Category

• Prescription
• Over-the-Counter (OTC)

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

A full report of Rheumatology Therapeutics Market available @ https://www.omrglobal.com/industry-reports/rheumatology-therapeutics-market

Global Rheumatology Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Aurinia Pharmaceuticals Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Eli Lilly
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Janssen Pharmaceuticals, Inc.
• Johnson & Johnson Private Ltd.
• Regeneron Pharmaceuticals Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rheumatology Therapeutics Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030 here

News-ID: 3267639 • Views:

More Releases from Orion Market Research

AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2033
AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2 …
AI-enabled imaging modalities market was valued at approximately USD 1.36 billion, and it is projected to reach around USD 19.78 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 34.67% from 2024 to 2033. AI-Enabled Imaging Modalities Market Overview The AI-enabled imaging modalities market is experiencing rapid growth, driven by advancements in artificial intelligence and machine learning technologies. These innovations are enhancing the capabilities of various imaging modalities, including
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Playe …
Global tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033. Tumor Tracking Systems Market Overview The tumor tracking systems market is experiencing steady growth, driven by the increasing incidence of cancer and advancements in imaging and tracking technologies. These systems improve the precision of
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry Growths to 2033
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry …
Tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033. Tumor Tracking Systems Market Overview The tumor tracking systems market is experiencing steady growth, driven by the increasing prevalence of cancer and advancements in imaging technologies. These systems play a crucial role in enhancing the
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and G …
SNP genotyping market was valued at approximately USD 31.66 billion, and it is projected to reach around USD 238.25 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 20.1% from 2024 to 2034. SNP genotyping Market Overview The SNP genotyping market is experiencing significant growth, driven by advancements in genotyping technologies, an increase in the prevalence of genetic disorders, and the expansion of pharmacogenomics and precision medicine initiatives. This

All 5 Releases


More Releases for Rheumatology

Increasing Autoimmune Disease Prevalence Drives Rheumatology Therapeutics Market …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Rheumatology Therapeutics Market Size Growth Forecast: What to Expect by 2025? The market for rheumatology therapeutics has seen robust growth in the recent past. The market size is expected to expand from $42.4 billion in 2024 to $44.61 billion in 2025, marking a compound annual growth rate (CAGR) of
Rheumatology Therapeutics Market to Hit $59.1 Billion by 2030
◉ Global Rheumatology Therapeutics Market Set to Reach USD 59.1 Billion by 2030, Driven by Aging Population and Innovation The global rheumatology therapeutics market is poised for steady growth, projected to reach nearly USD 59.1 billion by 2030, expanding at a CAGR of 2.7% from 2024 to 2030, according to Maximize Market Research. This growth is fueled by an aging global population, rising prevalence of rheumatic diseases, and continuous advancements in
Rheumatology Therapeutics Market Insights, Status and Forecast to 2030
The latest research study released by AMA on the Rheumatology Therapeutics Market offers over 181 pages of analysis on business strategies employed by key and emerging industry players. It provides insights into current market developments, landscape, technologies, drivers, opportunities, market outlook, and status. The market study is segmented by key regions driving market growth. The Rheumatology Therapeutics study combines qualitative and quantitative market data, primarily collected and validated through primary
Rheumatology Therapeutics Market 2023 Driving Factors Forecast Research 2029
Rheumatology Therapeutics market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). Therapeutic drugs are used to slow down the progression of certain autoimmune rheumatic diseases such as rheumatic arthritis (RA). The increasing prevalence of RA globally has bolstered the launch of novel therapeutic agents and favorable refurbishment policies for high-cost treatment products are some of the factors driving the market growth. According to the
Current trends in Rheumatology, Orthopedics, and Arthroplasty
2nd International Conference on Rheumatology, Orthopedics and Arthroplasty December 05-06, 2022 | Dubai, UAE Theme: Current Trends in Rheumatology, Orthopedics and Arthroplasty Rheumatology 2022 will provide an international platform for all Speakers, Delegates, Surgeons, Research Scholars, Orthopedic Physicians, Orthopedic Surgeons, Rheumatologists, Orthopedic and Rheumatology Research Fellows, Orthopedic and Rheumatology Faculty, Directors and Chair Persons, Health Care Professionals, Orthopedic and Rheumatology Medical Students, Orthopedics Medical Colleges, Universities, Orthopedics Devices Designers etc. Audience Profile: ·
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology